Počet záznamů: 1
Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors
- 1.
SYSNO ASEP 0504625 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors Tvůrce(i) Kubczak, M. (PL)
Szustka, A. (PL)
Błoński, J. Z. (PL)
Gucký, T. (CZ)
Misiewicz, M. (PL)
Kryštof, Vladimír (UEB-Q) RID, ORCID
Robak, Z. (PL)
Rogalińska, M. (PL)Celkový počet autorů 8 Zdroj.dok. Molecular Medicine Reports. - : Spandidos Publications - ISSN 1791-2997
Roč. 19, č. 5 (2019), s. 3593-3603Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. GR - Řecko Klíč. slova Alkylator ; Anticancer agents ; Apoptosis ; Chronic lymphocytic leukemia ; Cyclin-dependent kinase inhibitor ; In vitro cell incubations ; Monoclonal antibody ; Necrosis ; Viability Vědní obor RIV EB - Genetika a molekulární biologie Obor OECD Hematology CEP LO1204 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy GA15-15264S GA ČR - Grantová agentura ČR Způsob publikování Open access Institucionální podpora UEB-Q - RVO:61389030 UT WOS 000465868800024 EID SCOPUS 85064113948 DOI 10.3892/mmr.2019.10007 Anotace Chronic lymphocytic leukemia (CLL) treatment is improving, however, some patients do not respond to therapy. Due to the high heterogeneity in disease development, there is an urgent need for personalization of therapy. In the present study, the response of leukemic mononuclear cells to anticancer drugs used for CLL treatment (cladribine + mafosfamide, CM or CM combined with rituximab, RCM) was compared with the response to new cyclin-dependent kinase (CDK) inhibitors: BP14 and BP30. Viable apoptotic and necrotic cells were quantified by flow cytometry using propidium iodide and Yo-Pro stains. CDK inhibitors were studied in several doses to determine the reduction of necrosis and simultaneous increase of apoptosis in leukemic cell incubations with anticancer agents. The distinct cell response to applied doses/anticancer agents was observed. Results obtained in the current manuscript confirmed that modulation of doses is important. This was particularly indicated in results obtained at 24 h of cells incubation with anticancer agent. While an important time for analysis of anticancer response efficacy (monitoring of apoptosis induction potential) seems to be 48 h of cells exposition to anticancer agents. High variability in response to the drugs revealed that both the nature and the dose of the anticancer agents could be important in the final effect of the therapy. The present findings support the thesis that personalized medicine, before drug administration in the clinic, could be important to avoid the application of ineffective therapy. Pracoviště Ústav experimentální botaniky Kontakt David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469 Rok sběru 2020 Elektronická adresa http://doi.org/10.3892/mmr.2019.10007
Počet záznamů: 1